Loading
Loading
Growth Hormone & Secretagogues · 5mg
Janoshik-tested · 10 vials per kit
HGH (Somatropin) is a recombinant human growth hormone studied in preclinical and clinical research for its anabolic and metabolic properties. Research has examined its potential to stimulate IGF-1 production, promote lipolysis, enhance nitrogen retention, support bone density, and regulate carbohydrate metabolism. Studies have explored applications in growth hormone deficiency, body composition, and aging-related decline.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Chemical Properties
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
HGH Fragment 176-191
Somatotropin C-Terminal Fragment
HGH Fragment 176-191 is a synthetic peptide corresponding to C-terminal amino acids 176-191 of human growth hormone (hGH). Developed at Monash University (Melbourne), this fragment was identified as responsible for hGH's lipolytic activity while being structurally distinct from the N-terminal domains that drive IGF-1 stimulation and anabolic or diabetogenic effects.
The fragment interacts with growth hormone receptors on adipocytes to activate hormone-sensitive lipase (HSL) and inhibit lipoprotein lipase (LPL), shifting the adipocyte towards lipolysis and away from fatty acid uptake and triglyceride storage. Unlike intact hGH, the fragment does not bind IGF-1 receptors, does not stimulate IGF-1 production, and does not produce insulin resistance or hyperglycaemia — isolating the fat-mobilising property of GH.
Animal studies demonstrated selective visceral and subcutaneous fat reduction without effects on lean mass or blood glucose. Human phase I/II trials (Metabolic Pharmaceuticals, Melbourne) showed dose-dependent weight and fat loss over 12 weeks with favourable safety profiles. Research also includes combination studies with dietary interventions and resistance training protocols.
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
